NanoViricides Files for Rare Pediatric Disease Designation for Measles Drug

Why It Matters

The PRV could deliver hundreds of millions in cash, accelerating NanoViricides’ growth while filling a critical therapeutic gap for measles, especially among infants and vaccine‑non‑responders.

Key Takeaways

• NanoViricides seeks Rare Pediatric Disease designation for measles drug NV‑387.
• Designation could earn a Priority Review Voucher worth $150‑$250 million.
• No approved antivirals for measles; unmet medical need highlighted.
• Vaccine‑breakthrough cases and infants under one year drive market potential.
• Orphan and pediatric designations may accelerate FDA review and funding.

Summary

NanoViricides announced that it has filed an FDA application for Rare Pediatric Disease designation for its investigational measles antiviral, NV‑387. The move positions the company to qualify for a Priority Review Voucher (PRV) if the drug receives approval, a mechanism that can be sold to other developers for substantial cash.

The designation also dovetails with an orphan‑drug filing, promising more frequent FDA interactions and an accelerated review timeline. NanoViricides highlighted the absence of any approved antiviral therapy for measles and cited recent animal‑model success in humanized mice. The company underscored the public‑health gap created by infants too young for vaccination and a CDC‑reported 10% breakthrough rate among fully vaccinated individuals.

CEO Dr. Anil Diwan noted that PRVs have fetched as much as $250 million in the past, with recent transactions around $150‑$160 million, providing a potential windfall that could fund commercialization without relying on product sales. He also emphasized the urgency of a therapeutic option given periodic measles spikes in the United States.

If approved, NV‑387 could become the first antiviral for measles, offering a treatment for vulnerable pediatric cohorts and generating significant non‑dilutive capital through voucher sales, thereby reshaping the company’s financial outlook and the broader measles‑treatment landscape.

Original Description

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to announce that the company has filed an application for Rare Pediatric Disease Drug Designation with the U.S. FDA’s Office of Orphan Products Development for NV-387 as a treatment for measles.

The RPDD application is expected to be combined with the company’s previously submitted Orphan Drug Designation application for NV-387, filed in February 2026, as part of a broader regulatory strategy to advance the drug candidate.

If granted, the designation would make NanoViricides eligible for a Priority Review Voucher upon approval of NV-387. PRVs are tradable assets that have recently commanded values of approximately $160 million, reflecting their ability to accelerate regulatory review timelines for other drugs.

Diwan emphasized the potential impact of NV-387, stating the therapy could become an important tool in addressing the resurgence of measles in the United States and globally. He added that treatment with NV-387 may support rapid recovery while helping to reduce complications, including the rare but serious post-measles “immune amnesia” effect. Currently, there are no approved antiviral treatments specifically for measles, highlighting a significant unmet medical need.

The Rare Pediatric Disease Priority Review Voucher program was reauthorized in February 2026 under the Consolidated Appropriations Act, reinforcing incentives for companies developing therapies targeting serious pediatric conditions.

Measles cases have been rising in the United States, with more than 1,600 laboratory-confirmed cases reported across 33 states as of early April 2026, according to the CDC. While hospitalization rates have declined compared to 2025, the disease continues to pose risks, particularly among pediatric populations, which account for approximately 70% of cases.

#proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #measles #nanoviricides #NV387 #OrphanDrugDesignation #AntiviralTherapy #ClinicalTrials #PhaseII #OrphanDrugDesignation #FDA #Measles #Antiviral #HealthcareInnovation #MedicalResearch #Biopharma #PediatricHealth #GlobalHealth